UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.18, ss.129-134, 2008 (SCI İndekslerine Giren Dergi)
The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4 to 26 months. We evaluated the efficacy and toxicity of ifosfamide (1), mesna (M) and doxorubicin (A) (IMA) chemotherapy regimen retrospectively in patients with metastatic or recurrent uterine sarcomas.